Apollomics (APLM) Competitors $5.92 +0.12 (+1.98%) Closing price 03:58 PM EasternExtended Trading$5.82 -0.10 (-1.69%) As of 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APLM vs. TENX, LSTA, QTTB, RLYB, LGVN, CASI, FBLG, AYTU, NAII, and DAREShould you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include Tenax Therapeutics (TENX), Lisata Therapeutics (LSTA), Q32 Bio (QTTB), Rallybio (RLYB), Longeveron (LGVN), CASI Pharmaceuticals (CASI), FibroBiologics (FBLG), Aytu BioPharma (AYTU), Natural Alternatives International (NAII), and Dare Bioscience (DARE). These companies are all part of the "pharmaceutical products" industry. Apollomics vs. Its Competitors Tenax Therapeutics Lisata Therapeutics Q32 Bio Rallybio Longeveron CASI Pharmaceuticals FibroBiologics Aytu BioPharma Natural Alternatives International Dare Bioscience Apollomics (NASDAQ:APLM) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership. Which has stronger earnings and valuation, APLM or TENX? Tenax Therapeutics has lower revenue, but higher earnings than Apollomics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApollomics$1.49M4.37-$53.86MN/AN/ATenax TherapeuticsN/AN/A-$17.60M-$0.92-6.47 Does the media prefer APLM or TENX? In the previous week, Tenax Therapeutics had 5 more articles in the media than Apollomics. MarketBeat recorded 6 mentions for Tenax Therapeutics and 1 mentions for Apollomics. Apollomics' average media sentiment score of 1.87 beat Tenax Therapeutics' score of 0.46 indicating that Apollomics is being referred to more favorably in the media. Company Overall Sentiment Apollomics Very Positive Tenax Therapeutics Neutral Which has more risk & volatility, APLM or TENX? Apollomics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Do analysts rate APLM or TENX? Tenax Therapeutics has a consensus price target of $17.00, indicating a potential upside of 185.71%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tenax Therapeutics is more favorable than Apollomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Tenax Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Do insiders & institutionals have more ownership in APLM or TENX? 19.1% of Apollomics shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 3.1% of Tenax Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is APLM or TENX more profitable? Apollomics' return on equity of 0.00% beat Tenax Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ApollomicsN/A N/A N/A Tenax Therapeutics N/A -31.64%-30.61% SummaryTenax Therapeutics beats Apollomics on 8 of the 13 factors compared between the two stocks. Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLM vs. The Competition Export to ExcelMetricApollomicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.40M$3.10B$5.62B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E RatioN/A20.4930.2925.74Price / Sales4.37356.37463.41115.83Price / CashN/A43.0338.2159.48Price / Book1.328.608.826.15Net Income-$53.86M-$54.65M$3.25B$265.06M7 Day Performance3.41%5.43%4.05%2.80%1 Month Performance3.05%6.75%4.32%1.68%1 Year Performance-55.89%31.59%36.25%29.59% Apollomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLMApollomics0.4361 of 5 stars$5.92+2.0%N/A-58.7%$6.40M$1.49M0.0045Positive NewsGap UpTENXTenax Therapeutics1.9721 of 5 stars$6.07-1.8%$17.50+188.3%+46.7%$25.18MN/A-2.459News CoverageEarnings ReportAnalyst ForecastLSTALisata Therapeutics2.2912 of 5 stars$2.77+7.8%$23.50+748.4%-8.5%$23.87M$1M-1.2030Earnings ReportShort Interest ↑Analyst RevisionGap DownHigh Trading VolumeQTTBQ32 Bio2.7917 of 5 stars$1.96+1.3%$12.17+522.3%-94.9%$23.85M$1.16M-0.4039Short Interest ↓RLYBRallybio3.1589 of 5 stars$0.56+6.4%$10.00+1,676.2%-53.0%$23.55M$848K-0.5240Earnings ReportShort Interest ↓LGVNLongeveron3.7721 of 5 stars$1.57-8.5%$8.67+453.8%-67.7%$23.38M$2.39M-0.2520News CoverageEarnings ReportCASICASI Pharmaceuticals4.1583 of 5 stars$1.90-2.6%$4.00+110.5%-71.8%$23.37M$31.37M-0.75180News CoverageUpcoming EarningsGap DownHigh Trading VolumeFBLGFibroBiologics3.2231 of 5 stars$0.57-6.2%$13.00+2,176.7%-68.7%$22.82MN/A-1.6010Short Interest ↑Gap DownAYTUAytu BioPharma3.7897 of 5 stars$2.51-5.2%$10.00+298.2%-5.3%$22.59M$81M-3.49160News CoverageNAIINatural Alternatives International1.5442 of 5 stars$3.64-0.4%N/A-26.8%$22.46M$125.48M-2.62290DAREDare Bioscience2.3693 of 5 stars$2.40+0.3%$12.00+400.8%-49.8%$21.81M$10K-14.2130News CoverageEarnings ReportShort Interest ↓ Related Companies and Tools Related Companies Tenax Therapeutics Competitors Lisata Therapeutics Competitors Q32 Bio Competitors Rallybio Competitors Longeveron Competitors CASI Pharmaceuticals Competitors FibroBiologics Competitors Aytu BioPharma Competitors Natural Alternatives International Competitors Dare Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLM) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access